Efficacy and Safety of Zoledronic Acid for the Treatment of Osteoporosis in Men
NCT ID: NCT00097825
Last Updated: 2012-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
288 participants
INTERVENTIONAL
2004-04-30
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis
NCT00439647
Zoledronic Acid for Osteoporosis in the Elderly
NCT00558012
Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older
NCT00132808
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
NCT00404820
Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
NCT00046254
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Zoledronic Acid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* History of severe liver, kidney or eye disease
25 Years
85 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Catalina Pointe Clinical Research Inc.
Tucson, Arizona, United States
Diablo Clinical Research
Walnut Creek, California, United States
Colorado Center for Bone Research
Lakewood, Colorado, United States
Radiant Research
Stuart, Florida, United States
United Osteoporosis Center
Gainesville, Georgia, United States
Northwestern Center for Clinical Research
Chicago, Illinois, United States
Mercy Arthritis and Osteoporosis Center
Des Moines, Iowa, United States
St. Joseph Hospital
Bangor, Maine, United States
Osteoporosis and Clinical Trials Center
Hagerstown, Maryland, United States
New Mexico Clinical Research and Osteoporosis Center
Albuquerque, New Mexico, United States
Helen Hayes Hospital
West Haverstraw, New York, United States
UC Bone Health and Osteoporosis Center
Cincinnati, Ohio, United States
Oregon Health Sciences University
Portland, Oregon, United States
Radiant Research
Wyomissing, Pennsylvania, United States
Hampton Roads Center for Clinical Research
Norfolk, Virginia, United States
McGuire VA Medical Center
Richmond, Virginia, United States
Garvan Institute of Medical Research
Sydney, New South Wales, Australia
Repatriation General Hospital
Daw Park, South Australia, Australia
Keogh Institute for Medical Research
Nedlands, Western Australia, Australia
Clinical Research Center
Vancouver, British Columbia, Canada
QEII HealthSciences Center
Halifax, Nova Scotia, Canada
Charlton Medical Building
Hamilton, Ontario, Canada
Centre De Recherche Clinique De Laval
Laval, Quebec, Canada
Royal Victoria Hospital
Montreal, Quebec, Canada
Groupe de Recherche en Rhumatologie et Maladies Osseuses
Sainte-Foy, Quebec, Canada
Saskatoon Osteoporosis Center
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, Bucci-Rechtweg C, Su G. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc. 2010 Nov;141(11):1365-70. doi: 10.14219/jada.archive.2010.0082.
Related Links
Access external resources that provide additional context or updates about the study.
For information regarding US facilities, click this hyperlink.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CZOL446M2308
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.